Abstract
Acute agitation is a frequent reason for emergency psychiatric intervention. It is important to intervene early to avoid escalation of agitation to aggression. Reducing risk by using effective treatments will result in fewer instances of seclusion and restraint, and fewer injuries to staff and patients. This paper will first review the epidemiology of aggressive behavior and mental disorders, followed by a discussion of assessment and diagnostic considerations. The pathophysiology of safety risk is discussed within the context of the model of the “triune brain.” Pharmacological treatment strategies for acute episodes of agitated behavior will be discussed in detail. This includes newer formulations of novel antipsychotics such as liquids and rapidly disintegrating tablets, as well as intramuscular preparations.
Similar content being viewed by others
REFERENCES
Keckich WA: Violence as a manifestation of akathisia. JAMA 240:2185, 1978.
Siris SG: Three cases of akathisia and “acting out.” Journal of Clinical Psychiatry 46:395–397, 1985.
Dietch JT, Jennings RK: Journal of Clinical Psychiatry 49:184–188, 1988.
Walsh MT, Dinan TG: Selective serotonin reuptake inhibitors and violence: A review of the available evidence. Acta Psychiatrica Scandinavica 104(2):84–91, 2001.
Convit A, Isay D, Otis D, et al: Characteristics of repeatedly assaultive psychiatric inpatients. Hospital and Community Psychiatry 41:1112–1115, 1990.
Owen C, Tarantello C, Jones M, et al: Repetitively violent patients in psychiatric units. Psychiatric Services 49(11):1458–1461, 1998.
Regier DA, Farmer ME, Rae DS, et al: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264:2511–2518, 1990.
Swanson JW: Mental disorder, substance abuse, and community violence: An epidemiological approach, in Violence and Mental Disorder: Developments in Risk Assessment. Edited by Monahan J, Steadman HJ. Chicago, The University of Chicago Press, 1994.
Link BG, Cullen FT, Andrews H: The violent and illegal behavior of mental patients reconsidered. American Sociological Review 57:275–292, 1992.
Link BG, Stueve A: Psychotic symptoms and the violent/illegal behavior of mental patients compared to community controls, in Violence and Mental Disorder: Developments in Risk Assessment. Edited by Monahan J, Steadman HJ. Chicago, The University of Chicago Press, 1994.
Steadman HJ, Mulvey EP, Monahan J, et al: Violence by people discharged from acute psychiatric inpatient facilities and others in the same neighborhoods. Archives of General Psychiatry 55:393–401, 1998.
Czobor P, Volavka J: Violence in the mentally ill: Questions remain [Letter]. Archives of General Psychiatry 56:193, 1999.
Binder RL, McNiel DE: Effects of diagnosis and context on dangerousness. American Journal of Psychiatry 145:728–732, 1988.
Tanke ED, Yesavage JA: Characteristics of assaultive patients who do and do not provide visible cues of potential violence. American Journal of Psychiatry 142:1409–1413, 1985.
Holden C: Paul MacLean and the triune brain. Science 204:1066–1068, 1979.
MacLean PD: The triune brain in conflict. Psychotherapy and Psychosomatics 28:207–220, 1977.
MacLean PD: Brain evolution relating to family, play, and the separation call. Archives of General Psychiatry. 42:405–417, 1985.
MacLean PD: Evolutionary psychiatry and the triune brain. Psychological Medicine 15:219–221, 1985.
Lindenmayer JP: The pathophysiology of agitation. Journal of Clinical Psychiatry. 2000;61(Suppl. 14):5–10, 2000.
Link BG, Stueve A, Phelan J: Psychotic symptoms and violent behaviors: Probing the components of “threat/control-override” symptoms. Social Psychiatry and Psychiatric Epidemiology 33(Suppl. 1):S55–S60, 1998.
Citrome L, Volavka J: Clinical management of persistent aggressive behavior in schizophrenia. Part II: Long-term pharmacotherapeutic strategies. Essential Psychopharmacology 5(1):17–30, 2002.
Citrome L, Volavka J: Atypical antipsychotics—Revolutionary or incremental advance? Expert Review of Neurotherapeutics 2(1):69–88, 2002.
Citrome L, Green L: The dangerous agitated patient: What to do right now. Postgraduate Medicine 87:231–236, 1990.
Salzman C: Use of benzodiazepines to control disruptive behavior in inpatients. Journal of Clinical Psychiatry 49(Suppl. 12):13–15, 1988.
Greenblatt DJ, Divoll M, Harmatz JS, et al: Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. Journal of Pharmaceutical Sciences 71:248–252, 1982.
Greenblatt DJ, Shader RI, Franke K, et al: Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. Journal of Pharmaceutical Sciences 68:57–63, 1979.
Clinton JE, Sterner S, Stelmachers Z, et al: Haloperidol for sedation of disruptive emergency patients. Annals of Emergency Medicine 16:319–322, 1987.
Thomas H, Schwartz E, Petrilli R: Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Annals of Emergency Medicine 21:407–413, 1992.
Shale JH, Shale CM, Mastin WD: A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. Journal of Clinical Psychiatry 64(5):500–505, 2003.
Lischke V, Behne M, Doelken P, et al: Droperidol causes a dose-dependent prolongation of the QT interval. Anesthesia and Analgesia 79:983–986, 1994.
Battaglia J, Moss S, Rush J, et al: Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine 15(4):335–340, 1997.
Hughes DH: Acute psychopharmacological management of the aggressive psychotic patient. Psychiatric Services 50:1135–1137, 1999.
Currier GW, Simpson GM: Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. Journal of Clinical Psychiatry 62(3):153–157, 2001.
Currier GW, Chou JC, Feifel D, et al: Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidal and lorazepam. Journal of Clinical Psychiatry 65(3):386–394, 2004.
Baker RW, Kinon BJ, Maguire GA, et al: Effectiveness of rapid initial dose escalation of up to 40 mg per day of oral olanzapine in acute agitation. Journal of Clinical Psychopharmacology 23(4):342–348, 2003.
Lesem MD, Zajecka JM, Swift RH, et al: Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. Journal of Clinical Psychiatry 62:12–18, 2001.
Daniel DG, Potkin SG, Reeves KR, et al: Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial. Psychopharmacology (Berlin) 155:128–134, 2001.
Pfizer, Inc: Briefing Document for Ziprasidone Mesylate for Intramuscular Injection, FDA Psychopharmacological Drugs Advisory Committee, February 15, 2001 (available at www.fda.gov).
Brook S, Lucey JV, Gunn KP: Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Journal of Clinical Psychiatry 61(12):933–941, 2000.
Brook, S: Intramuscular ziprasidone: Moving beyond the conventional in the treatment of acute agitation in schizophrenia. Journal of Clinical Psychiatry 64(suppl 19):13–18, 2003.
Eli Lilly and Company: Briefing Document for Zyprexa IntraMuscular (olanzapine for injection), FDA Psychopharmacological Drugs Advisory Committee, January 11, 2001, with Addendum February 14, 2001 (available at www.fda.gov).
Wright P, Birkett M, David SR, et al: Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. American Journal of Psychiatry 158:1149–1151, 2001.
Breier A, Meehan K, Birkett M, et al: A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry 59(5):441–448, 2002.
Meehan K, Zhang F, David S, et al: A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology 21:389–397, 2001.
Meehan KM, Wang H, David SR, et al: Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 26(4):494–504, 2002.
Battaglia J, Lindborg SR, Alaka K, et al: Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine 21(3):192–198, 2003.
Lindborg SR, Beasley CM, Alaka K, et al: Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Research 119(1–2):113–123, 2003.
Wright P, Meehan K, Birkett M, et al: A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clinical Therapeutics 25(5):1420–1428, 2003.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Citrome, L. New Treatments for Agitation. Psychiatr Q 75, 197–213 (2004). https://doi.org/10.1023/B:PSAQ.0000031791.53142.85
Issue Date:
DOI: https://doi.org/10.1023/B:PSAQ.0000031791.53142.85